Geode Capital Management’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $37.4M | Buy |
4,718,183
+427,554
| +10% | +$2.73M | ﹤0.01% | 1788 |
|
|
2026
Q1 | $24.9M | Buy |
4,290,629
+14,640
| +0.3% | +$97.1K | ﹤0.01% | 1879 |
|
|
2025
Q4 | $33.6M | Buy |
4,275,989
+135,815
| +3% | +$1.07M | ﹤0.01% | 1724 |
|
|
2025
Q3 | $33.7M | Buy |
4,140,174
+489,486
| +13% | +$3.25M | ﹤0.01% | 1722 |
|
|
2025
Q2 | $17.1M | Buy |
3,650,688
+244,862
| +7% | +$1.12M | ﹤0.01% | 2039 |
|
|
2025
Q1 | $18.7M | Buy |
3,405,826
+54,400
| +2% | +$220K | ﹤0.01% | 1938 |
|
|
2024
Q4 | $11.4M | Buy |
3,351,426
+17,956
| +0.5% | +$57.8K | ﹤0.01% | 2293 |
|
|
2024
Q3 | $9.5M | Buy |
3,333,470
+93,091
| +3% | +$239K | ﹤0.01% | 2415 |
|
|
2024
Q2 | $7.29M | Buy |
3,240,379
+195,015
| +6% | +$393K | ﹤0.01% | 2515 |
|
|
2024
Q1 | $6.73M | Buy |
3,045,364
+153,287
| +5% | +$397K | ﹤0.01% | 2544 |
|
|
2023
Q4 | $6.8M | Buy |
2,892,077
+118,784
| +4% | +$219K | ﹤0.01% | 2542 |
|
|
2023
Q3 | $5.16M | Buy |
2,773,293
+91,488
| +3% | +$210K | ﹤0.01% | 2621 |
|
|
2023
Q2 | $7.03M | Buy |
2,681,805
+151,100
| +6% | +$385K | ﹤0.01% | 2506 |
|
|
2023
Q1 | $4.13M | Buy |
2,530,705
+97,994
| +4% | +$123K | ﹤0.01% | 2721 |
|
|
2022
Q4 | $3.23M | Buy |
2,432,711
+79,689
| +3% | +$112K | ﹤0.01% | 2870 |
|
|
2022
Q3 | $3.67M | Buy |
2,353,022
+179,468
| +8% | +$297K | ﹤0.01% | 2833 |
|
|
2022
Q2 | $3.35M | Buy |
2,173,554
+1,011,664
| +87% | +$2.13M | ﹤0.01% | 2924 |
|
|
2022
Q1 | $2.97M | Buy |
1,161,890
+156,890
| +16% | +$383K | ﹤0.01% | 3058 |
|
|
2021
Q4 | $2.94M | Buy |
1,005,000
+300,830
| +43% | +$650K | ﹤0.01% | 3174 |
|
|
2021
Q3 | $1.73M | Buy |
704,170
+131,207
| +23% | +$381K | ﹤0.01% | 3426 |
|
|
2021
Q2 | $2.33M | Sell |
572,963
-212,738
| -27% | -$812K | ﹤0.01% | 3220 |
|
|
2021
Q1 | $3.54M | Buy |
785,701
+66,697
| +9% | +$360K | ﹤0.01% | 2950 |
|
|
2020
Q4 | $3.54M | Buy |
719,004
+108,800
| +18% | +$544K | ﹤0.01% | 2781 |
|
|
2020
Q3 | $3.62M | Buy |
610,204
+125,118
| +26% | +$500K | ﹤0.01% | 2575 |
|
|
2020
Q2 | $1.29M | Sell |
485,086
-3,850
| -0.8% | -$13.4K | ﹤0.01% | 3061 |
|
|
2020
Q1 | $953K | Buy |
488,936
+134,474
| +38% | +$578K | ﹤0.01% | 3041 |
|
|
2019
Q4 | $2.5M | Buy |
354,462
+15,952
| +5% | +$132K | ﹤0.01% | 2875 |
|
|
2019
Q3 | $3.33M | Buy |
338,510
+14,834
| +5% | +$167K | ﹤0.01% | 2623 |
|
|
2019
Q2 | $3.7M | Buy |
323,676
+53,794
| +20% | +$565K | ﹤0.01% | 2583 |
|
|
2019
Q1 | $2.71M | Buy |
269,882
+187,190
| +226% | +$2.4M | ﹤0.01% | 2677 |
|
|
2018
Q4 | $1.41M | Buy |
82,692
+15,459
| +23% | +$310K | ﹤0.01% | 2952 |
|
|
2018
Q3 | $1.18M | Buy |
+67,233
| New | +$1.46M | ﹤0.01% | 3149 |
|
Other funds holding XERS
RA
Geode Capital Management's XERS Position: Q2 2026 in Review
Geode Capital Management increased its Xeris Biopharma Holdings (XERS) stake by 10% in Q2 2026, buying an estimated $2.73M and bringing the position to 4,718,183 shares worth $37.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1788.
Geode Capital Management first reported a position in XERS in Q3 2018 and has held it in 32 quarters since. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.
- Geode Capital Management held 4,718,183 shares of Xeris Biopharma Holdings worth $37.4M as of Q2 2026.
- Geode Capital Management bought 427,554 Xeris Biopharma Holdings shares in Q2 2026, an estimated $2.73M.
- Xeris Biopharma Holdings made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1788 holding.
- Geode Capital Management first reported a position in Xeris Biopharma Holdings in Q3 2018 and has held it in 32 quarters since.
- 239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.